Retinal Disorder Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2025-2034

The Global Retinal Disorder Treatment Market was valued at USD 18.3 billion in 2024 and is estimated to grow at a CAGR of 6.7% to reach USD 34.8 billion by 2034,ac driven by the rising prevalence of retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. The aging global population and increasing incidence of diabetes have intensified the demand for effective treatment options, boosting market growth.

Macular degeneration, particularly age-related, is the leading contributor to market value due to its widespread impact on older adults. According to the World Health Organization (WHO), the number of people aged 60 and older is expected to reach 1.4 billion by 2030 and double by 2050. This demographic shift has resulted in a larger patient base requiring advanced therapeutic solutions, reinforcing macular degeneration’s dominance with a projected market value of USD 20.03 billion by 2034 and a CAGR of 7.4% between 2025 and 2034.

In terms of dosage form, eye drops led the market in 2024, generating USD 3.5 billion. Their non-invasive administration, patient convenience, and improvements in drug delivery systems have made them a preferred choice, especially for early-stage retinal conditions. As awareness of preventive care rises, eye drops are expected to maintain a strong market presence through the forecast period.

Among distribution channels, hospital pharmacies generated the highest revenue in 2024 with USD 8.6 billion, driven by the complexity of retinal disorders that require advanced diagnostics, injectable therapies, and close monitoring—all of which are typically administered in hospital settings. Their integration with ophthalmology departments and comprehensive access to reimbursement mechanisms make them a critical channel for advanced treatments.

North America dominated the global market in 2024 with a value of USD 7.6 billion, holding a 41.8% share. This dominance is supported by a high disease burden, advanced healthcare infrastructure, favorable reimbursement policies, and the presence of leading market players such as Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., and Novartis AG. The region’s CAGR is forecasted at 6.3% during the same period, maintaining its leadership in the global landscape.

Companies such as AbbVie Inc., Alimera Sciences, Amgen Inc., Apellis Pharmaceuticals, Astellas Pharma Inc., Bayer AG, Biogen Inc., Bausch + Lomb Corporation, Celltrion Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceuticals Co. Ltd., and Sandoz Group AG are bolstering their market positions through strategic R&D investments, biosimilar developments, and global distribution expansion. Innovations like long-acting formulations and gene therapies are being increasingly explored to address the growing patient need for efficient and accessible treatment options.

As awareness initiatives and access to screening improve across emerging economies, and technology continues to evolve, the retinal disorder treatment market is poised for sustained growth and therapeutic innovation throughout the next decade. Show more